voda schreef op 2 december 2021 10:49:
Galapagos: The Investment Thesis Is More Appealing Than Ever
Dec. 02, 2021 2:53 AM ETGalapagos NV (GLPG)ESALF, ESALY, GILD1 Comment
Galapagos is in the midst of a transformation process that is expected to result in a completely different company by 2023.
Galapagos has over $5.5 billion in cash, an approved drug and a broad pipeline with a market capitalization of only $3.2 billion.
Jyseleca is approved in Japan and is expected to generate €500 million annually in sales in Europe in the medium term.
Since the stock is trading below liquidation value, it is easy to generate shareholder value with little risk.seekingalpha.com/article/4472945-gala...